Nancy Wysenski
Known title: DirectorCIK: 0001294596
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Transaction History
| CYTK | ▲ Buy | Grant | 75 | $6K | 7/15/2026 | View on chart |
| CYTK | ▲ Buy | Grant | 2,851 | $0 | 5/27/2026 | View on chart |
| CYTK | ▲ Buy | Grant | 95 | $6K | 4/15/2026 | View on chart |
| CYTK | ▲ Buy | Grant | 98 | $6K | 1/15/2026 | View on chart |
| CYTK | ▲ Buy | Grant | 99 | $6K | 10/15/2025 | View on chart |
| CYTK | ▲ Buy | Grant | 164 | $6K | 7/15/2025 | View on chart |
| CYTK | ▲ Buy | Grant | 7,333 | $0 | 5/14/2025 | View on chart |
| CYTK | ▲ Buy | Grant | 162 | $6K | 4/15/2025 | View on chart |
| CYTK | ▲ Buy | Grant | 127 | $6K | 1/2/2025 | View on chart |
| CYTK | ▲ Buy | Grant | 118 | $6K | 10/1/2024 | View on chart |
| CYTK | ▲ Buy | Grant | 114 | $0 | 7/1/2024 | View on chart |
| CYTK | ▲ Buy | Grant | 5,600 | $0 | 5/15/2024 | View on chart |
| CYTK | ▲ Buy | Grant | 74 | $6K | 1/2/2024 | View on chart |
| CYTK | ▲ Buy | Grant | 224 | $6K | 10/2/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,957 | — | 7/7/2023 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,430 | $43K | 7/7/2023 | View on chart |
| CYTK | ▲ Buy | Grant | 187 | $6K | 7/3/2023 | View on chart |
| CYTK | ▲ Buy | Grant | 5,000 | $0 | 5/10/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,250 | $195K | 5/9/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 35,000 | $1.1M | 5/9/2023 | View on chart |
| ALKS | ▼ Sell | Open Market | 41,250 | $1.3M | 5/9/2023 | View on chart |
| CYTK | ▲ Buy | Grant | 149 | $6K | 4/3/2023 | View on chart |
| CYTK | ▲ Buy | Grant | 126 | $6K | 1/3/2023 | View on chart |
| CYTK | ▲ Buy | Grant | 110 | $6K | 10/3/2022 | View on chart |
| CYTK | ▲ Buy | Grant | 137 | $6K | 7/1/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 7,585 | — | 6/14/2022 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 695 | $19K | 6/14/2022 | View on chart |
| CYTK | ▲ Buy | Grant | 5,000 | $0 | 5/10/2022 | View on chart |
| CYTK | ▲ Buy | Grant | 146 | $6K | 4/1/2022 | View on chart |
| CYTK | ▲ Buy | Grant | 122 | $6K | 1/3/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,578 | — | 12/2/2021 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,339 | $30K | 12/2/2021 | View on chart |
| CYTK | ▲ Buy | Grant | 153 | $6K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cytokinetics Launches ASPEN-HCM Real-World Study
Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.
Cytokinetics Launches ASPEN-HCM Real-World Study. Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.